Core Viewpoint - The Hong Kong stock market is entering a significant phase for annual IPOs, with six companies launching their offerings and scheduled to list on December 30, reflecting a strong demand for quality enterprises to utilize market opportunities [1][2]. Group 1: Companies and Their Offerings - Six companies, including Insilico Medicine, Wuyishijie, Xunce, Meilian Holdings, Woan Robotics, and Linqingxuan, are set to launch IPOs, covering diverse sectors such as AI pharmaceuticals, digital twins, home robotics, and high-end skincare [1][2]. - Insilico Medicine, known as a pioneer in AI pharmaceuticals, has set its IPO price at HKD 24.05, aiming to raise HKD 2.277 billion, making it the largest among the six [1]. - Wuyishijie, focusing on digital twin and Physical AI technologies, plans to issue 23.975 million shares at HKD 30.5 each, with a potential fundraising of up to HKD 841 million if the over-allotment option is exercised [2]. - Xunce, a real-time data infrastructure service provider, is expected to raise between HKD 1.08 billion and HKD 1.23 billion, with a share price range of HKD 48-55 [2]. - Woan Robotics, backed by industry figure Li Zexiang, is entering the home robotics sector, while Linqingxuan is offering 13.96645 million shares at HKD 77.77 each [2]. Group 2: Market Trends and Analysis - The concentration of tech and new consumer companies in the IPO market indicates a shift in the structure of IPOs, with technology and new consumption becoming the dominant forces [1][3]. - The traditional industrial sector, represented by Meilian Holdings, highlights the financing needs of transforming traditional industries, aligning with the "technology-led, diversified supplement" structure of the Hong Kong IPO market [3]. - The influx of new IPOs may lead to market differentiation, where the quality of cornerstone investors and the ability to deliver on performance will be critical in distinguishing the companies [3]. - The simultaneous issuance of multiple new stocks may create a fund diversion effect, impacting the demand for public offerings and international placements [3].

New IPOs - The largest biotech IPO in Hong Kong for 2025 is initiated by Insilico Medicine (03696), which boasts the fastest global progress in AI drug development [1] - Lin Qingxuan (02657) will conduct its IPO from December 18 to December 23, attracting cornerstone investors like Fidelity [1] - Woan Robotics (06600) is set to launch its IPO during the same period, with an expected listing date of December 30 [1] - Meilian Holdings (02671) and Wuyi Vision (06651) will also hold their IPOs from December 18 to December 23, both expected to list on December 30 [1] - Xun Ce (03317) will follow the same IPO schedule, with a listing anticipated on December 30 [1] - Zhihui Mining (02546) achieved a remarkable 5248.15 times subscription in its public offering, with a listing date of December 19 [1] - China National Airlines (00753) plans to invest in Shenzhen Airlines' equity financing, with Kunhang Investment, a state-owned entity, being shortlisted [1] - Sensetime-W (00020) intends to place 1.75 billion new Class B shares, aiming to raise approximately HKD 3.146 billion [1] - Fosun Pharma (02196) is enhancing its overseas innovative drug strategy by signing a cooperation and option agreement with Clavis Bio [1] - WuXi AppTec (02359) invested around EUR 30 million to acquire a 3.22% stake in a French biopharmaceutical fund [1] - Minhua Holdings (01999) plans to acquire 100% equity in the American soft furniture company Gainline Recline Intermediate Corp [1] Share Buybacks - Tencent Holdings (00700) repurchased 1.055 million shares for HKD 636 million on December 18 [2] - Xiaomi Group-W (01810) spent HKD 151 million to buy back 3.75 million shares on the same day [2] - COSCO Shipping Holdings (01919) repurchased 5.9 million shares for HKD 80.557 million [2] - Country Garden Services (06098) bought back 2.7 million shares for HKD 17.136 million [2] - Jiangsu Ninghu Expressway (00177) saw an increase of 52.862 million shares by Yunsong Capital [2]

IPO 申购指南 卧安机器人（6600.HK） 建议谨慎申购 2025-12-18 星期四 【招股详情】 保荐人 国泰海通，国泰君安国际，华泰国际 上市日期 2025 年 12 月 30 日（星期二） 招股价格 63~81 港元/股 集资额 15.049 亿港元（按 73 港元/股中间价计算） 每手股数 100 股 入场费 8,181.69 港元 招股日期 2025 年 12 月 18 日-2025 年 12 月 23 日 国元证券认购截止日期 2025 年 12 月 22 日 招股总数 2,222.23 万股(可予调整及视乎超额配售权的行使情况而定) 国际配售 2,000 万股(可予调整及视乎超额配售权的行使情况而定)，约占 90% 公开发售 222.23 万股(可予调整及视乎超额配售权的行使情况而定)，约占 10% 【申购建议】 根据弗若斯特沙利文报告，公司是全球领先的家庭机器人系统的全球提供 商，主要市场包括日本、欧洲及北美，并致力于构建以智能家庭机器人产品 为核心的生态系统。公司的产品主要包括：1）增强型执行机器人，包括灵活 型技巧机器人（如门锁机器人、窗帘机器人及手指机器人）、增强型移动机 器人（如 ...

AI具身家庭机器人第一股卧安机器人(深圳)股份有限公司(OneRobotics (Shenzhen) Co., Ltd. 下称"卧安机 器人")，今日正式宣布启动全球公开发售(股票代码：06600)，计划12月30日于香港联交所主板上市，国 泰君安及华泰国际担任联席保荐人。 此次卧安机器人香港IPO的基石投资阵容十分强大，9家基石投资人合计认购份额超7亿港元、占比5 成。其中，高瓴为最大基石投资人，还有Cithara、Infini、中国东方、Wind Sabre、Yield Royal、Sage等 明星投资机构加持。这一顶级组合，为公司上市提供了坚实的资本背书。 三大AI具身技术体系，奠定系统级智能基石 数据显示，卧安机器人2024年全年营收突破6亿元人民币，2022年至2024年的复合年增长率高达 49.0%，彰显出强劲的增长动能。2025年上半年，卧安机器人已成功扭亏为盈，实现期内溢利约2790.3 万元人民币，这标志其商业模式已跑通并进入可持续盈利阶段。与此同时，通过持续优化销售渠道结 构，卧安机器人盈利能力持续提升，2025年上半年整体毛利率达到54.2%，反映出强大的产品价值与成 本控制能力。 从区 ...

智通财经APP获悉，AI具身家庭机器人第一股卧安机器人(深圳)股份有限公司(OneRobotics (Shenzhen) Co., Ltd. 下称"卧安机器人")，今日正式宣布启动全球 公开发售(股票代码：06600)，计划12月30日于香港联交所主板上市，国泰君安及华泰国际担任联席保荐人。 此次卧安机器人香港IPO的基石投资阵容十分强大，9家基石投资人合计认购份额超7亿港元、占比5成。其中，高瓴为最大基石投资人，还有Cithara、 Infini、中国东方、Wind Sabre、Yield Royal、Sage等明星投资机构加持。这一顶级组合，为公司上市提供了坚实的资本背书。 三大AI具身技术体系，奠定系统级智能基石 资料显示，卧安机器人的核心竞争力源于其深厚的全栈技术积累。公司自主研发并掌握机器人定位与环境构建技术、AI机器视觉控制技术及分布式神经控 制网络技术，并成功将其应用于覆盖家庭、运动、陪伴等多场景的产品矩阵。 卧安机器人拥有哈尔滨工业大学的技术基因，其创始人李志晨与潘阳为哈工大同窗，奠定了公司深厚的科研底色。公司不仅获得李泽湘教授、高秉强教授等 学界权威的持续背书与深度参与，更在成长过程中吸引了 ...

Group 1: IPO Information - The IPO for 英矽智能 (03696.HK) is open for subscription from December 18 to December 23, with a global offering of 94,690,500 shares, where 10% is for public offering in Hong Kong and 90% for international offering. The offer price is set at HKD 24.05 per share, with a minimum investment of HKD 12,146.27 for 500 shares [2][4] - The IPO for 五一视界 (06651.HK) is also open for subscription from December 18 to December 23, with a global offering of 23,975,200 shares, where 5% is for public offering in Hong Kong and 95% for international offering. The offer price is set at HKD 30.50 per share, with a minimum investment of HKD 6,161.51 for 200 shares [8][10] - 迅策 (03317.HK) is offering 22,500,000 shares from December 18 to December 23, with 10% for public offering in Hong Kong and 90% for international offering. The price range is HKD 48.00 to HKD 55.00 per share, with a minimum investment of HKD 5,555.47 for 100 shares [13][15] - 美联股份 (02671.HK) is offering 24,600,000 shares from December 18 to December 23, with 10% for public offering in Hong Kong and 90% for international offering. The price range is HKD 7.10 to HKD 9.16 per share, with a minimum investment of HKD 2,775.71 for 300 shares [19][21] - 卧安机器人 (06600.HK) is offering 22,222,300 shares from December 18 to December 23, with 10% for public offering in Hong Kong and 90% for international offering. The price range is HKD 63.00 to HKD 81.00 per share, with a minimum investment of HKD 8,181.69 for 100 shares [25][27] - 林清轩 (02657.HK) is offering 13,966,500 shares from December 18 to December 23, with 10% for public offering in Hong Kong and 90% for international offering. The offer price is set at HKD 77.77 per share, with a minimum investment of HKD 3,927.72 for 50 shares [30][32] Group 2: Financial Performance - 英矽智能 reported revenues of USD 30.15 million, USD 51.18 million, USD 85.83 million, USD 59.69 million, and USD 27.46 million for the years 2022, 2023, 2024, and the six months ending June 30, 2025, respectively. The net losses for the same periods were USD 221.83 million, USD 211.64 million, USD 17.10 million, USD 8.03 million, and USD 19.22 million [7] - 五一视界's revenue grew from RMB 169.98 million in 2022 to RMB 256.30 million in 2023, and further to RMB 287.36 million in 2024. The revenue for the six months ending June 30, 2025, was RMB 53.82 million, showing a 62.0% increase from the same period in 2024. The net losses for the same periods were RMB 189.79 million, RMB 87.08 million, RMB 78.97 million, RMB 65.07 million, and RMB 94.05 million [12][12] - 迅策's revenue for the years 2022, 2023, and 2024 was RMB 288 million, RMB 530 million, and RMB 632 million, respectively, with net losses of RMB 97 million, RMB 63 million, and RMB 98 million for the same years [18] - 美联股份 reported revenues of RMB 1,902.84 million, RMB 1,453.18 million, RMB 1,523.03 million, RMB 509.51 million, and RMB 1,424.11 million for the years 2022, 2023, 2024, and the six months ending June 30, 2025, respectively. The net profits for the same periods were RMB 87.71 million, RMB 62.13 million, RMB 70.78 million, RMB 13.61 million, and RMB 62.63 million [23] - 卧安机器人的 revenue for the years 2022, 2023, and 2024 was RMB 274.60 million, RMB 457.26 million, and RMB 609.92 million, respectively, with net losses of RMB 86.98 million, RMB 16.38 million, and RMB 3.07 million. The company reported a net profit of RMB 27.90 million for the six months ending June 30, 2025 [29][29] - 林清轩's total revenue for the years 2022, 2023, 2024, and the six months ending June 30, 2025, was RMB 691.15 million, RMB 805.00 million, RMB 1,209.64 million, RMB 530.45 million, and RMB 1,051.77 million, respectively. The company transitioned from a net loss of RMB 5.93 million in 2022 to a net profit of RMB 84.52 million in 2023 and further increased to RMB 186.83 million in 2024 [34]

卧安机器人(06600.HK)发布公告，公司拟全球发售2222.23万股股份，其中香港发售股份222.23万股，国 际发售股份2000.00万股，另有333.33万股超额配股权。招股日期为12月18日至12月23日，最高发售价 81.00港元，每手买卖单位100股，入场费约8181.69港元。 卧安机器人预计于2025年12月30日在主板上市，国泰君安融资有限公司、华泰金融控股（香港）有限公 司为联席保荐人。 公司是家庭机器人系统全球提供商，特别关注日本、欧洲及北美市场，并致力于构建以智慧家庭机器人 产品为核心的生态系统。 公司2023年度、2024年度、2025年半年度截至6月30日止，净利润分别为-1637.60万元、-307.40万元、 2790.30万元，同比变动幅度为81.17%、81.23%、304.55%。（数据宝） （文章来源：证券时报网） 全球发售预计募资总额为16.00亿港元，募资净额15.05亿港元，募资用途为用于持续提升公司的研发能 力；用于扩大公司的销售渠道及地区覆盖及提升公司品牌的全球知名度；用作一般营运资金及公司用 途；用于偿还未偿还银行贷款。 公司引入HACF, LP、Cith ...

卧安机器人(06600.HK)发布公告，公司拟全球发售2222.23万股股份，其中香港发售股份222.23万股，国 际发售股份2000.00万股，另有333.33万股超额配股权。招股日期为12月18日至12月23日，最高发售价 81.00港元，每手买卖单位100股，入场费约8181.69港元。 全球发售预计募资总额为16.00亿港元，募资净额15.05亿港元，募资用途为用于持续提升公司的研发能 力；用于扩大公司的销售渠道及地区覆盖及提升公司品牌的全球知名度；用作一般营运资金及公司用 途；用于偿还未偿还银行贷款。 卧安机器人预计于2025年12月30日在主板上市，国泰君安融资有限公司、华泰金融控股（香港）有限公 司为联席保荐人。 公司是家庭机器人系统全球提供商，特别关注日本、欧洲及北美市场，并致力于构建以智慧家庭机器人 产品为核心的生态系统。 公司引入HACF, LP、Cithara Global Multi-Strategy SPC — Bosideng Industry Investment Fund SP、Infini Global Master Fund、China Orient Enhanced In ...

公司是家庭机器人系统的全球提供商，主要市场包括日本、欧洲及北美，并致力于构建以智慧家庭机器 人产品为核心的生态系统。根据弗若斯特沙利文报告，公司为全球领先的家庭机器人系统提供商，提供 专为多种家庭生活场景设计的广泛家庭机器人品类。公司的产品主要包括(i)增强型执行机器人，包括灵 活型技巧机器人(如门锁机器人、窗帘机器人及手指机器人)、增强型移动机器人(如多功能家用机器人) 以及运动机器人;(ii)感知与决策系统，包括智能中枢、智能传感器及智能摄像头;及(iii)其他智能家庭产 品与服务，如照明及电动工具及智能家电。公司以技术研发和产品创新为驱动核心，发挥集研发、生产 及销售于一体的产业链优势，持续加强家庭机器人技术在广泛的家庭生活场景(覆盖智能操控、家务劳 动、智慧管家、养老护理、安全防护及能源管理)的应用及深耕，并不断提升家庭场景覆盖纵深及机器 人智能自主学习和决策能力，为用户提供完整丰富的智能家庭生活生态系统。 卧安机器人(06600)于2025年12月18日至12月23日招股，该公司拟全球发售2222.23万股，其中香港发售 占10%，国际发售占90%，另有15%超额配股权，每股发售价63-81港元。每 ...

格隆汇12月18日丨卧安机器人(06600.HK)发布公告，公司拟全球发售2222.23万股H股，中国香港发售股 份222.23万股，国际发售股份2000万股(以上可予重新分配且视乎超额配股权行使与否而定)；2025年12 月18日至12月23日招股，预期定价日为12月24日；发售价将为每股发售股份63.00-81.00港元，H股的每 手买卖单位将为100股，国泰君安国际及华泰国际为联席保荐人；预期股份将于2025年12月30日开始在 联交所买卖。 集团是家庭机器人系统的全球提供商，主要市场包括日本、欧洲及北美，并致力于构建以智慧家庭机器 人产品为核心的生态系统。根据弗若斯特沙利文报告，集团为全球领先的家庭机器人系统提供商，提供 专为多种家庭生活场景设计的广泛家庭机器人品类。集团的产品主要包括(i)增强型执行机器人，包括灵 活型技巧机器人(如门锁机器人、窗帘机器人及手指机器人)、增强型移动机器人(如多功能家用机器人) 以及运动机器人；(ii)感知与决策系统，包括智能中枢、智能传感器及智能摄像头；及(iii)其他智能家庭 产品与服务，如照明及电动工具及智能家电。集团以技术研发和产品创新为驱动核心，发挥集研发、生 ...